Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRAEMOS: T-DM1 and Osimertinib in HER2-Positive NSCLC
NCT03784599Phase 2Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2018
- Primary completion
- May 2021
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab emtansine in non-small cell lung cancer (NSCLC), sponsored by Netherlands Cancer Institute. Started Dec 2018; status: terminated.
02
Drugs
trastuzumab emtansine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03784599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03784599.